The Scaling Paradox: Why Biotech Breakthroughs Die in the Factory Layer with Dima Romashin

Episode notes

Join Dima Romashin, CEO and Co-Founder of Efferon, for an unvarnished examination of the execution bottleneck threatening modern life sciences. While the biotech sector is experiencing an unprecedented boom in discovery, an industry-wide crisis looms at the industrialization layer: brilliant therapeutics and medical devices frequently fail not because the science is flawed, but because it cannot be reliably replicated at scale. Bringing a background as a manufacturing executive at a $100M+ enterprise to the deep-tech ecosystem, Dima argues that true clinical impact only occurs when a breakthrough can be successfully manufactured by the millions. In this episode, we explore how Efferon is scaling its revolutionary blood purification platform and redefining the rules of biotech capital formation. Insights You’ll Learn: The Scale-Up Mirage: Why optimizing a biomaterial or therapeutic device in a sterile lab setup completely falls apart when transitioning to high-yield factory automation.

• The Foundation Bet: Why Pivot Built the System of Record Before the AI with Marc-Antoine Lacroix64 / 100
• The Solar Marathon: Why True Circularity Takes Time and How to Scale It with Dr. Jan-Philipp Mai
• The Frontline Blind Spot: Why General AI Fails the Factory Floor with Garth Coleman
• The Frictionless Front Desk: Demystifying AI in the Service Economy with Filip Linek
• The Accountability Era: How Computer Vision and AI Are Reshaping Hollywood's Monetization Engine with Cihan Fuat Atkin